Suppr超能文献

乳腺钼靶筛查对乳腺癌死亡率的有效性——一项使用德国健康保险数据模拟目标试验的研究方案

Effectiveness of Mammography Screening on Breast Cancer Mortality - A Study Protocol for Emulation of Target Trials Using German Health Claims Data.

作者信息

Braitmaier Malte, Kollhorst Bianca, Heinig Miriam, Langner Ingo, Czwikla Jonas, Heinze Franziska, Buschmann Laura, Minnerup Heike, García-Albéniz Xabiér, Hense Hans-Werner, Karch André, Zeeb Hajo, Haug Ulrike, Didelez Vanessa

机构信息

Department of Biometry and Data Management, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.

Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.

出版信息

Clin Epidemiol. 2022 Nov 2;14:1293-1303. doi: 10.2147/CLEP.S376107. eCollection 2022.

Abstract

BACKGROUND

The efficacy of mammography screening in reducing breast cancer mortality has been demonstrated in randomized trials. However, treatment options - and hence prognosis - for advanced tumor stages as well as mammography techniques have considerably improved since completion of these trials. Consequently, the effectiveness of mammography screening under current conditions is unclear and controversial. The German mammography screening program (MSP), an organized population-based screening program, was gradually introduced between 2005 and 2008 and achieved nation-wide coverage in 2009.

OBJECTIVE

We describe in detail a study protocol for investigating the effectiveness of the German MSP in reducing breast cancer mortality in women aged 50 to 69 years based on health claims data. Specifically, the proposed study aims at estimating per-protocol effects of several screening strategies on cumulative breast cancer mortality. The first analysis will be conducted once 10-year follow-up data are available.

METHODS AND ANALYSIS

We will use claims data from five statutory health insurance providers in Germany, covering approximately 37.6 million individuals. To estimate the effectiveness of the MSP, hypothetical target trials will be emulated across time, an approach that has been demonstrated to minimize design-related biases. Specifically, the primary contrast will be in terms of the cumulative breast cancer mortality comparing the screening strategies of "never screen" versus "regular screening as intended by the MSP".

ETHICS AND DISSEMINATION

In Germany, the utilization of data from health insurances for scientific research is regulated by the Code of Social Law. All involved health insurance providers as well as the responsible authorities approved the use of the health claims data for this study. The Ethics Committee of the University of Bremen determined that studies based on claims data are exempt from institutional review. The findings of the proposed study will be published in peer-reviewed journals.

摘要

背景

乳腺钼靶筛查在降低乳腺癌死亡率方面的疗效已在随机试验中得到证实。然而,自这些试验完成以来,晚期肿瘤阶段的治疗选择以及预后情况,还有乳腺钼靶技术都有了显著改善。因此,当前条件下乳腺钼靶筛查的有效性尚不清楚且存在争议。德国乳腺钼靶筛查项目(MSP)是一项基于人群的有组织筛查项目,于2005年至2008年逐步推行,并于2009年实现全国覆盖。

目的

我们详细描述一项研究方案,该方案基于健康保险理赔数据,调查德国MSP在降低50至69岁女性乳腺癌死亡率方面的有效性。具体而言,拟开展的研究旨在估计几种筛查策略对累积乳腺癌死亡率的符合方案效应。一旦有了10年随访数据,将进行首次分析。

方法与分析

我们将使用来自德国五家法定健康保险提供商的理赔数据,覆盖约3760万人。为了估计MSP的有效性,将随时间模拟假设的目标试验,这种方法已被证明可将与设计相关的偏差降至最低。具体而言,主要对比将是比较“从不筛查”与“按照MSP预期进行定期筛查”这两种筛查策略的累积乳腺癌死亡率。

伦理与传播

在德国,利用健康保险数据进行科学研究受《社会法典》监管。所有参与的健康保险提供商以及相关主管部门均批准将健康保险理赔数据用于本研究。不来梅大学伦理委员会认定,基于理赔数据的研究无需经过机构审查。拟开展研究的结果将发表在同行评审期刊上。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验